Crigler-Najjar syndrome

2 trials 2 recruiting MedDRA PT
2 Registered trials
2 Recruiting
1 Unique sponsors
2 Unique IMPs
2 Commercial trials
Drug classes (ATC)
L Oncology (ATC L) 1
— ATC code not specified 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 2 substances
Phase II: 1 Phase I (First in Human): 1

Filter these 2 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 2 trials

Phase II

1 trial
  • Genethon Commercial
    ADENO-ASSOCIATED VIRAL VECTOR SEROTYPE 2/8 CONTAINING THE HUMAN UGT1A1 GENE; IMLIFIDASE
    2023-510405-18-00 1 country 2024 n=3 Orphan
    Recruiting

Phase I (First in Human)

1 trial
  • Genethon Commercial
    ADENO-ASSOCIATED VIRAL VECTOR SEROTYPE 2/8 CONTAINING THE HUMAN UGT1A1 GENE
    2023-507007-60-00 3 countries 2018 n=17 Orphan
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Genethon Commercial 2 Phase II, Phase I (First in Human) 2
New trials by year
2024
1
← All indication landscapes